Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C / Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C
Rev. méd. Chile
;
139(6): 704-709, jun. 2011. ilus
Article
in Spanish
| LILACS
| ID: lil-603114
ABSTRACT
Background:
The current treatment recommendation for chronic hepatitis C virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks, depending on the viral genotype. The aim of the therapy is to obtain a sustained virological response.Aim:
To report our experience in the treatment of chronic hepatitis C. Material andMethods:
Analysis of 52 patients treated between September 2000 and June 2009. Patients with genotype 1 or 5 were treated with peginterferon alpha 2a (180 ug/week) and ribavirin (1000 mg/day for those weighing less than 75 kg and 1200 mg/day for those weighing more than 75 kg) during 48 weeks. Patients with genotypes 2 and 3 were treated for 24 weeks with the same dose of peginterferon and ribavirin 800 mg /day.Results:
Viral genotypes 1, 2, 3 and 5 were present in 81, 4, 11 and 4 percent of patients, respectively. Twenty four patients (46 percent), 18 with genotype 1, achieved a sustained viral response. Age was the only variable that infl uenced the response to treatment.Conclusions:
Approximately half of the patients with chronic hepatitis C, achieve a sustained viral response with peginterferon and ribavirin.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Ribavirin
/
Interferon-alpha
/
Hepatitis C, Chronic
Type of study:
Practice guideline
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
South America
/
Chile
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2011
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Hospital Clínico Universidad de Chile/CL
/
Hospital Naval Almirante Nef/CL
Similar
MEDLINE
...
LILACS
LIS